Friday, 16 October 2026European Markets

AVENIR TELECOM Stock Was 11.18% Up On Wednesday

Loading stream...

(vianews) - the market ended the session with avenir telecom (avt.pa) jumping 11.18% to €0.29 on wednesday, after two successive sessions in a row of losses. cac 40 slid 0.2% to €7,324.76, following the last session's downward trend on what was a somewhat bearish trend trading session today.

about avenir telecom

avenir telecom s.a. retails and distributes mobiles, smartphones, and accessories. the company offers chargers, cables, protection screens and cases, memory, and usb products, multiports, hubs, and other products under the energizer brand. it also designs and manufactures accessories under oxo brand. the company sells its products in 55 countries. avenir telecom s.a. was founded in 1989 and is based in marseille, france.

earnings per share

as for profitability, avenir telecom has a trailing twelve months eps of €-0.023.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, avenir telecom's stock is considered to be overbought (>=80).

volatility

avenir telecom's last week, last month's, and last quarter's current intraday variation average was a negative 4.71%, a positive 5.36%, and a positive 9.47%.

avenir telecom's highest amplitude of average volatility was 14.28% (last week), 14.32% (last month), and 9.47% (last quarter).

volume

today's last reported volume for avenir telecom is 3409040 which is 39.21% below its average volume of 5608150.

more news about avenir telecom (avt.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com